Información del artículo
Abstract
Charcot-Marie-Tooth disease is the most frequent inherited neuropathy with a prevalence ratio in Spain of 28.2 cases / 100,000 inhabitants. It is a sensory-motor polyneuropathic syndrome, either demyelinating or axonal, which might be transmitted with autosomal dominant, autosomal recessive or X-linked pattern. Despite presenting with a stereotyped semiology, this a genetically complex syndrome comprising 36 localized loci with 30 cloned mutated genes. Here we briefly review the pathogenic mechanisms of these gene mutations. We address the pathophysiology of pes cavus, which is a cardinal manifestation of the disease. In the early clinical stages, forefoot pes cavus is most probably due to selective denervation of foot musculature, and particularly of the lumbricals, which causes an imbalance between intrinsic and extrinsic foot muscles leading to toe clawing, retraction of plantar fascia, approximation of the pillars of the longitudinal arch, and shortening of the Achilles tendon. We review the disease diagnosis and treatment.
Keywords:
Axon
Charcot-Marie-Tooth disease
Dejerine-Sottas disease
Gene mutation
Genetic neuropathy
Pes cavus
Magnetic resonance
Myelin
Nerve conduction velocity
Vitamin C
Resumen
La enfermedad de Charcot-Marie-Tooth es la neuropatía hereditaria más frecuente con una prevalencia en España de 28,2 casos/100.000 habitantes. Se trata de un síndrome polineuropático sensitivo-motor, desmielinizante o axonal, que puede transmitirse con herencia autosómica dominante, autosómica recesiva, o ligada al cromosoma X. Pese a su semiología estereotipada, es un síndrome genéticamente complejo, dado que se han localizado 36 loci con una treintena de genes mutantes clonados. Analizamos los mecanismos patogénicos de estas mutaciones génicas. Abordamos la fisiopatología del pie cavo, que es manifestación cardinal de la enfermedad. En estadios clínicos iniciales, el pie cavo probablemente sea desencadenado por una desnervación selectiva de la musculatura intrínseca del pie, que causa un desequilibrio entre sus músculos intrínsecos y extrínsecos con dedos en garra, retracción de la fascia plantar, elevación del arco plantar, y acortamiento del tendón de Aquiles. Revisamos el diagnóstico y tratamiento de la enfermedad.
Palabras clave:
Axón
Enfermedad de Charcot-Marie-Tooth
Enfermedad de Dejerine-Sottas
Mielina
Mutación génica
Neuropatía genética
Pie cavo
Resonancia magnética
Velocidad de conducción nerviosa
Vitamina C
El Texto completo está disponible en PDF
References
[1.]
O. Combarros, J. Calleja, J.M. Polo, J. Berciano.
Prevalence of hereditary motor and sensory neuropathy in Cantabria.
Acta Neurol Scand, 75 (1987), pp. 9-12
[2.]
J.M. Charcot, P. Marie.
Sur une forme particulière d’atrophie musculaire progressive, souvent familiale, débutant par les pieds et les jambes et atteignant plus tard les mains.
Rev Méd Paris, 6 (1886), pp. 97-138
[3.]
H.H. Tooth.
The peroneal type of progressive muscular atrophy.
HK Lewis, (1886),
[4.]
J. Dejerine, J. Sottas.
Sur la névrite interstitielle, hypertrophique et progressive de l’enfance. Affection souvent familiale et à début infantile, caractérisée par une atrophie musculaire des extrémités, avec troubles marqués de la sensibilité et ataxie des mouvements et relevant d’une névrite interstitielle hypertrophique á marche ascendante, avec lésions médullaires consécutives.
C R Soc Biol (Paris), 45 (1893), pp. 63-96
[5.]
J. Berciano, M.T. Berciano, O. Combarros.
Original descriptions of peroneal muscular atrophy.
Muscle Nerve, 28 (2003), pp. 251-252
[6.]
F. Buchthal, F. Behse.
Peroneal muscular atrophy (PMA) and related disorders. I. Clinical manifestations as related to biopsy findings, nerve conduction and electromyography.
Brain, 100 (1977), pp. 41-66
[7.]
J. Dejerine, André-Thomas.
Sur la névrite interstitielle hypertrophique et progressive de l’enfance (2e observation suivie d’autopsie).
Nouv Iconogr Salpêt, 19 (1906), pp. 477-509
[8.]
A.E. Harding, P.K. Thomas.
The clinical features of hereditary motor and sensory neuropathy types I and II.
Brain, 103 (1980), pp. 259-280
[9.]
M.E. Shy, J.R. Lupski, P.H. Chance, C.J. Klein, P.J. Dyck.
Hereditary motor and sensory neuropathies.
Peripheral neuropathy, pp. 1623-1658
[10.]
D. Pareyson, C. Marchesi.
Diagnosis, natural history, and management of Charcot-Marie-Tooth disease.
Lancet Neurol, 8 (2009), pp. 654-667
[11.]
J. Berciano, O. Combarros, J. Figols, J. Calleja, A. Cabello, I. Silos, et al.
Hereditary motor and sensory neuropathy type II. Clinicopathological study of a family.
Brain, 109 (1986), pp. 897-914
[12.]
E. Nelis, J. Berciano, N. Verpoorten, K. Coen, I. Dierick, V. Van Gerwen, et al.
Autosomal dominant axonal Charcot-Marie-Tooth disease type 2 (CMT2G) maps to chromosome 12q12-q13.3.
J Med Genet, 41 (2004), pp. 193-197
[13.]
P.J. Dyck, et al.
Inherited neuronal degeneration and atrophy affecting peripheral motor, sensory, and autonomic neurons.
Peripheral neuropathy, pp. 825-867
[14.]
A. Niemann, P. Berger, U. Suter.
Pathomechanisms of mutant proteins in Charcot-Marie-Tooth disease.
Neuromolecular Med, 8 (2006), pp. 217-242
[15.]
K. Szigeti, J.R. Lupski.
Charcot-Marie-Tooth disease.
Eur J Hum Genet, 17 (2009), pp. 703-710
[16.]
M.M. Reilly, M.E. Shy.
Diagnosis and new treatments in genetic neuropathies.
J Neurol Neurosurg Psychiatry, 80 (2009), pp. 1304-1314
[17.]
J.R. Lupski, J.G. Reid, C. Gonzaga-Jauregui, D. Rio Deiros, D.C. Chen, L. Nazareth, et al.
Whole-genome sequencing in a patient with Charcot-Marie-Tooth neuropathy.
N Engl J Med, 362 (2010), pp. 1181-1191
[18.]
S. Züchner.
Peripheral neuropathies: whole genome sequencing identifies causal variants in CMT.
Nat Rev Neurol, 6 (2010), pp. 424-425
[19.]
K.G. Claeys, S. Züchner, M. Kennerson, J. Berciano, A. García, K. Verhoeven, et al.
Phenotypic spectrum of dynamin 2 mutations in Charcot-Marie-Tooth neuropathy.
Brain, 132 (2009), pp. 1741-1752
[20.]
E. Gallardo, K.G. Claeys, E. Nelis, A. García, A. Canga, O. Combarros, et al.
Magnetic resonance imaging findings of leg musculature in Charcot-Marie-Tooth disease type 2 due to dynamin 2 mutation.
J Neurol, 255 (2008), pp. 986-992
[21.]
P. Solla, A. Vannelli, A. Bolino, G. Marrosu, S. Coviello, M.R. Murru, et al.
Heat shock protein 27 R127W mutation: evidence of a continuum between axonal Charcot-Marie-Tooth and distal hereditary motor neuropathy.
J Neurol Neurosurg Psychiatry, 81 (2010), pp. 958-962
[22.]
T. Sevilla, T. Jaijo, D. Nauffal, D. Collado, M.J. Chumillas, J.J. Vilchez, et al.
Vocal cord paresis and diaphragmatic dysfunction are severe and frequent symptoms of GDAP1-associated neuropathy.
Brain, 131 (2008), pp. 3051-3061
[23.]
D. Ito, N. Suzuki.
Seipinopathy: a novel endoplasmic reticulum stress-associated disease.
Brain, 132 (2009), pp. 8-15
[24.]
M. Auer-Grumbach, B. Schlotter-Weigel, H. Lochmüller, G. Strobl-Wildemann, P. Auer-Grumbach, R. Fischer, et al.
Phenotypes of the N88S Berardinelli-Seip congenital lipodystrophy 2 mutation.
Ann Neurol, 57 (2005), pp. 415-424
[25.]
B. Nilius, G. Owsianik.
Channelopathies converge on TRPV4.
Nat Genet, 42 (2010), pp. 98-100
[26.]
M. Auer-Grumbach, A. Olschewski, L. Papić, H. Kremer, M.E. McEntagart, S. Uhrig, et al.
Alterations in the ankyrin domain of TRPV4 cause congenital distal SMA, scapuloperoneal SMA and HMSN2C.
Nat Genet, 42 (2010), pp. 160-164
[27.]
H.X. Deng, C.J. Klein, J. Yan, Y. Shi, Y. Wu, F. Fecto, et al.
Scapuloperoneal spinal muscular atrophy and CMT2C are allelic disorders caused by alterations in TRPV4.
Nat Genet, 42 (2010), pp. 165-169
[28.]
G. Landouré, A.A. Zdebik, T.L. Martinez, B.G. Burnett, H.C. Stanescu, H. Inada, et al.
Mutations in TRPV4 cause Charcot-Marie-Tooth disease type 2C.
Nat Genet, 42 (2010), pp. 170-174
[29.]
M. Zimo¿n, J. Baets, M. Auer-Grumbach, J. Berciano, A. García, E. López-Laso, et al.
Dominant mutations in the cation channel gene transient receptor potential vanilloid 4 cause an unusual spectrum of neuropathies.
Brain, 133 (2010), pp. 1798-1809
[30.]
J. Berciano, O. Combarros, J. Calleja, J.M. Polo, C. Leno.
The application of nerve conduction and clinical studies to genetic counseling in hereditary motor and sensory neuropathy type I.
Muscle Nerve, 12 (1989), pp. 302-306
[31.]
A. García, O. Combarros, J. Calleja, J. Berciano.
Charcot-Marie-Tooth disease type 1A with 17p duplication in infancy and early childhood: a longitudinal clinical and electrophysiologic study.
Neurology, 50 (1998), pp. 1061-1067
[32.]
M.E. Shy, A. Jáni, K. Krajewski, M. Grandis, R.A. Lewis, J. Li, et al.
Phenotypic clustering in MPZ mutations.
Brain, 127 (2004), pp. 371-384
[33.]
R.A. Mann, J. Missirian.
Pathophysiology of Charcot-Marie-Tooth disease.
Clin Orthop Relat Res, 234 (1988), pp. 221-228
[34.]
G.P. Guyton.
Current concepts review: orthopaedic aspects of Charcot-Marie-Tooth disease.
Foot Ankle Int, 27 (2006), pp. 1003-1010
[35.]
I.J. Alexander, K.A. Johnson.
Assessment and management of pes cavus in Charcot-Marie-Tooth disease.
Clin Orthop Relat Res, 246 (1989), pp. 273-281
[36.]
P.D. Thompson, P.K. Thomas.
Clinical patterns of peripheral neuropathy.
Peripheral neuropathy, pp. 1137-1161
[37.]
M.C. Tynan, L. Klenerman, T.R. Helliwell, R.H. Edwards, M. Hayward.
Investigation of muscle imbalance in the leg in symptomatic forefoot pes cavus: a multidisciplinary study.
Foot Ankle, 13 (1992), pp. 489-501
[38.]
M. Sabir, D. Lyttle.
Pathogenesis of pes cavus in Charcot-Marie-Tooth disease.
Clin Orthop Relat Res, 175 (1983), pp. 173-178
[39.]
J. Berciano, A. García, J. Calleja, O. Combarros.
Clinicoelectrophysiological correlation of extensor digitorum brevis muscle atrophy in children with Charcot-Marie-Tooth disease 1A duplication.
Neuromuscul Disord, 10 (2000), pp. 419-424
[40.]
J. Berciano, A. García, O. Combarros.
Initial semeiology in children with Charcot-Marie-Tooth disease.
Muscle Nerve, 27 (2003), pp. 34-39
[41.]
E. Gallardo, A. García, O. Combarros, J. Berciano.
Charcot-Marie-Tooth disease type 1A duplication: spectrum of clinical and magnetic resonance imaging features in leg and foot muscles.
Brain, 129 (2006), pp. 426-437
[42.]
P. Vinci, M. Serrao, F. Pierelli, G. Sandrini, V. Santilli.
Lower limb manual muscle testing in the early stages of Charcot-Marie-Tooth disease type 1A.
Funct Neurol, 21 (2006), pp. 159-163
[43.]
E. Passage, J.C. Norreel, P. Noack-Fraissignes, V. Sanguedolce, J. Pizant, X. Thirion, et al.
Ascorbic acid treatment corrects the phenotype of a mouse model of Charcot-Marie-Tooth disease.
Nat Med, 10 (2004), pp. 396-401
[44.]
M.M. Reilly, P. de Jonghe, D. Pareyson.
136th ENMC International Workshop: Charcot-Marie-Tooth disease type 1A (CMT1A), 8-10 April 2005, Naarden, The Netherlands.
Neuromuscul Disord, 16 (2006), pp. 396-402
[45.]
J. Burns, R.A. Ouvrier, E.M. Yiu, P.D. Joseph, A.J. Kornberg, M.C. Fahey, et al.
Ascorbic acid for Charcot-Marie-Tooth disease type 1A in children: a randomised, double-blind, placebo-controlled, safety and efficacy trial.
Lancet Neurol, 8 (2009), pp. 537-544
[46.]
J. Micallef, S. Attarian, O. Dubourg, P.M. Gonnaud, J.Y. Hogrel, T. Stojkovic, et al.
Effect of ascorbic acid in patients with Charcot-Marie-Tooth disease type 1A: a multicentre, randomised, double-blind, placebo-controlled trial.
Lancet Neurol, 8 (2009), pp. 1103-1110
[47.]
C. Verhamme, R.J. de Haan, M. Vermeulen, F. Baas, M. de Visser, I.N. van Schaik.
Oral high dose ascorbic acid treatment for one year in young CMT1A patients: a randomised, double-blind, placebocontrolled phase II trial.
BMC Med, 7 (2009), pp. 70
This study was financed by CIBERNED and the ISCIII (PI07/132E) Health Research Fund.
Copyright © 2011. Sociedad Española de Cirugía Ortopédica y Traumatología (SECOT). All rights reserved
